Applied Biosystems — UBS Life Science Conference 2008
35 slides from Applied Biosystems's conference presentation, Sep 24, 2008
Slide 1: UBS Life Science Conference
UBS Life Science Conference Greg Lucier, Chairman & CEO, Invitrogen Mark Stevenson, President & COO, Applied Biosystems September, 2008
Slide 2: Forward-looking statements
2 Certain statements contained in this presentations are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, and Invitrogen and Applera intend that such forward-looking statements be subject to the safe harbor created thereby. Forward-looking stat
Slide 3: Non-GAAP Measurements and Additional Information
3 Non-GAAP Measurements This presentation and discussion includes certain financial information which constitute “non-GAAP financial measures” as defined by the SEC. The GAAP measures which are most directly comparable to these measures, as well as a reconciliation of these measures with the most di
Slide 4: Agenda: Recap Invitrogen strategy
4 Transaction overview Strategic rationale The new company Agenda Recap Invitrogen strategy Integration & SOLiD Update
Slide 5: Our Focused Growth Strategy
5 Our Focused Growth Strategy...• Maintain leading proprietary portfolio • Differentiated service • Enhanced profitability 1. Optimize the core business • Emerging markets • Specialty cell systems • Cell biology • Instrumentation • Applied markets 2. Invest in high growth areas Acquisition of ABI ac
Slide 6: ...Has Delivered Strong Results
6 ...Has Delivered Strong Results The financial strength to acquire ABI Revenue ($M) PF Operating Margin (%) PF Operating Margin ($M) 1,151 1,282 1,369 2006 2007 6/30/08 FY LTM 275 319 361 2006 2007 6/30/08 FY LTM 9.0% CAGR 14.6% CAGR 23.9% 24.9% 26.4% 2006 2007 6/30/08 FY LTM
Slide 7: We Now Have the Infrastructure to Support a Major Acquisition
7 We Now Have the Infrastructure to Support a Major Acquisition Premier sales & marketing IT systems infrastructure Then (circa 2006) World-class website Integration of past acquisitions Robust product portfolio Now (circa 2008) Synchronized management systems
Slide 8: Agenda: Transaction overview
8 Transaction overview Strategic rationale Agenda Recap Invitrogen strategy The new company Integration & SOLiD Update
Slide 9: Transaction Overview
9 Transaction Overview Structure • Invitrogen will acquire all of Applied Biosystems shares • ABI shareholders to receive ~45% in cash, ~55% in Invitrogen shares or may elect all cash or all stock, subject to pro-ration • Invitrogen takes on additional $2.4B debt, total debt $3.5B • Headquarters: Ca
Slide 10: Creating an Impressive Global Leader
10 Creating an Impressive Global Leader Notes: LTM June 30, 2008 Before (Invitrogen) After (Combined) Revenue $1.4B $3.6B Pro-Forma Operating Margin % of revenue $361M 26% $816M 23% Free Cash Flow % of revenue $255M 19% $714M 20% Employees 4,700 ~10,000
Slide 11: Leading Player in the Life Sciences
11 Leading Player in the Life Sciences $2.2B $2.0B $1.7B $1.6B $1.6B $1.4B $0.8B $0.5B $1.4B $2.2B $3.6B ABI+IVGN ABI Sigma Agilent* Biorad Millipore Waters IVGN Quiagen Techne Illumina Revenues ($ billions, LTM 6/30/08) *BioAnalytical Measurement only
Slide 12: Agenda: Strategic rationale
12 Transaction overview Strategic rationale Agenda Recap Invitrogen strategy The new company Integration & SOLiD Update
Slide 13: Five Reasons ABI is a Perfect Fit For Invitrogen
13 Five Reasons ABI is a Perfect Fit For Invitrogen Scaled-up innovation engine 2 Enhanced commercial/ marketing network 3 High-growth markets 4 Financially attractive 5 Compelling Strategic Rationale 1 Complementary, best-in-class products
Slide 14: Creating A World-Class Biotech Tools Company
14 Creating A World-Class Biotech Tools Company 1 COMPLEMENTARY PRODUCTS Premier Consumables Provider Premier Systems Provider • Cell Culture Expertise • Labeling and Detection Chemistry • Molecular Biology Kits • DNA Sequencing • PCR / Real-Time PCR • Mass Spec Combined: A World-Class Biotech Tools
Slide 15: Creates Compelling End-to-End Workflow Solution for Our Customers
15 Creates Compelling End-to-End Workflow Solution for Our Customers 1 COMPLEMENTARY PRODUCTS • Innovate around workflows • Serve customers holistically Data Interpretation Detection / Analysis Sample Processing Sample Prep
Slide 16: Powerful Innovation Engine
16 1,200 2,400 3,600 IVGN ABI Combined (1) (2) $112M $190M >$300M IVGN ABI Combined (1) FY2007 Actuals (2) FY2008 Estimate (1) (2) Powerful Innovation Engine 2 INNOVATION ENGINE R&D Investment ($M) Patents & Licenses Unmatched scale of R&D – will drive growth + = + =
Slide 17: Complementary Commercial / Marketing Networks
17 Complementary Commercial / Marketing Networks 3 COMMERCIAL NETWORK • Excels at repeat business • e-Commerce expertise • 1,000+ supply centers • Strong relationships with bench scientists • Excels at systems sales • Global service infrastructure • Presence beyond life sciences • High level custome
Slide 18: Strong Platform for Expansion into High Growth Markets
18 Strong Platform for Expansion into High Growth Markets 4 HIGH GROWTH MARKETS Market Segment Market Growth Rate IVGN ABI Combined Capabilities 7-9% 10-13% >35% 14-16% Cell Biology $6B Applied Markets $9B Next Gen Sequencing $200M Emerging Geographies $1B
Slide 19: $175M of Synergies by Year
19 $175M of Synergies by Year 3 ~$60M total synergies realized in 2009 5 FINANCIALLY ATTRACTIVE • Raw material synergies • Overhead redundancies • Facility rationalization • R&D scale >$125M Cost Savings • ABI reagents thru IVGN channels • Apply IVGN mix & price discipline • Leverage ABI customer ac
Slide 20: Agenda: The new company
20 Transaction overview Strategic rationale The new company Agenda Recap Invitrogen strategy Integration & SOLiD Update
Slide 21: Our Vision for the Future
21 Our Vision for the Future Improving the human condition Our products enable and accelerate research in all areas from medicine... to food safety... to the environment Personalized medicine $1,000 genome Safer food and water New efficient fuels Healthier environment
Slide 22: New Company's Revenue Will Be Highly Diversified
22 By End Markets By Product Mix By Geography New Company’s Revenue Will Be Highly Diversified... Other 6% APAC 16% United States 44% Europe 34%... with a significant contribution from high-margin consumables Industry & Other 20% Pharma & Biotech 30% Academic & Govt 50% Instrument Reagent Systems 14
Slide 23: With An Attractive Cash Generating Business Model
23 ...With An Attractive Cash Generating Business Model 1. 75% consumables & services – high margin 2. High visibility – predictable, repeat business 3. Strong cash flow – low capital intensive business 4. Solid balance sheet – debt to EBITDA will be reduced to 3x within first year
Slide 24: Leading to Financial Strength in the Short Term
24 Leading to Financial Strength in the Short Term... (2009 Financial Guidance) Organic Revenue Growth Non-GAAP EPS(1) 2009E Mid single digits $2.60+(2) ABI acquisition highly accretive by 2010 Notes: (1) Non-GAAP EPS excludes certain acquisition related costs, including amortization of intangible a
Slide 25: And Through the Long Term
25 And Through the Long Term Revenue Mid single digit organic Non-GAAP Operating Margin % (1) Synergies + 50bps organic 23% High 20's 2008 proforma 4-6 Years Out (1) non-GAAP, excluding stock option expense Growth drivers: • Cost synergies • Organic productivity / fixed cost leveage (~50 bps / yr) $
Slide 26: The combined company: A World Class Biotechnology Tools Company
26 The combined company: A World Class Biotechnology Tools Company Scaled-up R&D Enhanced commercial networks High growth markets Financially attractive Complementary products
Slide 27: Agenda: Integration & SOLiD Update
27 Transaction overview Strategic rationale Agenda Recap Invitrogen strategy The new company Integration & SOLiD Update
Slide 28: The New Organization Combines Key Players from Both Companies
28 The New Organization Combines Key Players from Both Companies President and COO Mark Stevenson Chairman and CEO Greg Lucier CFO David Hoffmeister Human Resources Pete Leddy Global Services / Support Mark O’Donnell Molecular Biology Peter Dansky Genetic Systems Kip Miller Mass Spectrometry Laura L
Slide 29: Detailed Integration Plan
29 Detailed Integration Plan Blueprint Lockdown Target Day One Kickoff Late Jun Initiate & Plan Refine Plan Execute Integration (1-2 years) Prepare Signing 6/11 Signifies the task is complete or substantially in progress Day One Certification Integration Complete *A blueprint is a vision and integra
Slide 30: Integration Teams and Leadership
30 G. Lucier Integration Leader – M. Smedley ABI Integration Partner – Graham Howe Integration Partner – Deloitte Transaction Team Over 60 Personnel Involved in Integration Teams Support Teams Market Facing Teams Synergy Capture/ Value Creation Executive Leadership Integration Management Office (IMO
Slide 31: Next Generation Sequencing Driving New Discoveries
31 “Genomic Revolution” • Improved diagnostics & disease management • Transformed clinical trials... right treatments for right patients • Genomic baseline at birth... educated consumer and lifestyle choices improve human condition SOLiD Platform • Highest output/run of any platform • 2 base encodin
Slide 32: We Continue to Scale SOLiD Throughput
32 We Continue to Scale SOLiD Throughput... Reducing Customer Project Costs Customer Lab 4 13 20 Thruput (Gb) 0 10 20 30 40 50 60 October 07 February 08 May 08 October 08 Early 09 9 17 3 AB R&D
Slide 33: Enabling $10,000 Genome & Beyond
33 Enabling $10,000 Genome & Beyond • Continual improvement to system – SOLiD System beyond $10K Genome Small RNA Discovery Small RNA Kit 10K Genome High Density Slide Long Mate Pair Whole Transcriptome GEx End to End GEx Workflow Epigenomics DNA Methylation Workflow $5K Genome Ordered Array Slide $
Slide 34: The combined company: In Summary
34 The combined company: A World Class Biotechnology Tools Company IN SUMMARY Scaled-up R&D Enhanced commercial networks High growth markets Financially attractive Complementary products
Slide 35: UBS Life Science Conference
UBS Life Science Conference September, 2008 FINAL TRANSCRIPT
Applied Biosystems — UBS Life Science Conference 2008 on 6ix